October 30th 2024
Your daily dose of the clinical news you may have missed.
October 24th 2024
The expanded recommendation includes shots from Merck (PCV21) and Pfizer (PCV20), and could be a "practice-changing milestone," one executive said.
September 20th 2024
New report includes data on the safety and immunogenicity of the recently-approved PCV21 vaccine.
July 1st 2024
The novel vaccination is recommended as an option for adults aged 65 years and older who have not received a pneumococcal conjugate vaccine.
June 18th 2024
Capvaxive is the only pneumococcal vaccine formulated specifically to protect adults 50 years and older from IPD and elicited robust immune responses in both vaccine-naïve and vaccine-experienced adults.